4.5 Article

The MSH2 c.388_389del mutation shows a founder effect in Portuguese Lynch syndrome families

Journal

CLINICAL GENETICS
Volume 84, Issue 3, Pages 244-250

Publisher

WILEY-BLACKWELL
DOI: 10.1111/cge.12062

Keywords

founder mutation; Lynch syndrome; MSH2; recurrent mutation

Funding

  1. Fundacao para a Ciencia e a Tecnologia (FCT) [SFRH/BD/65326/2009]
  2. Fundação para a Ciência e a Tecnologia [SFRH/BD/65326/2009] Funding Source: FCT
  3. MRC [MC_U127527198, MC_PC_U127527198] Funding Source: UKRI
  4. Cancer Research UK [12076] Funding Source: researchfish
  5. Medical Research Council [MC_U127527198, MC_PC_U127527198] Funding Source: researchfish
  6. Worldwide Cancer Research [12-1087] Funding Source: researchfish

Ask authors/readers for more resources

The MSH2 c.388_389del mutation has occasionally been described in Lynch families worldwide. At the Portuguese Oncology Institute in Porto, Portugal, we have identified 16 seemingly unrelated families with this germline mutation. To evaluate if this alteration is a founder or a recurrent mutation we performed haplotype analysis in the 16 Portuguese index cases and 55 relatives, as well as in four index cases and 13 relatives reported from Germany, Scotland, England, and Argentina. In the Portuguese families we observed a shared haplotype of approximately 10Mb and all were originated from the north of Portugal. These results suggest that this alteration is a founder mutation in Portugal with a relatively recent origin. In the reported families outside Portugal with this mutation different haplotype backgrounds were observed, supporting the hypothesis that it occurred de novo on multiple occasions. We also conclude that the high proportion of families with the MSH2 c.388_389del mutation indicates that screening for this alteration as a first step may be cost-effective in the genetic testing of Lynch syndrome suspects of Portuguese ancestry, especially those originating from the north of Portugal.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available